Search Results
Your search for ,aLl matches 18308 pages
Showing 2901 - 2950Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma: 5-Year Results of the ZUMA-1 Trial
As reported in the journal Blood by Sattva S. Neelapu, MD, and colleagues, 5-year outcomes from the the phase II ZUMA-1 trial showed that axicabtagene ciloleucel was associated with maintained response in one-third of patients with refractory large B-cell lymphoma. The estimated 5-year overall...
First-Line Pembrolizumab in Older Patients With dMMR Metastatic Colorectal Cancer
In a retrospective cohort study reported in JAMA Network Open, Saberzadeh-Ardestani et al found that first-line pembrolizumab was associated with clinically significant prolongation of survival outcomes in mostly older patients with mismatch repair–deficient (dMMR) metastatic colorectal cancer....
Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer
In the phase II CALYPSO study reported in the Journal of Clinical Oncology, Suárez et al found that the combination of the MET inhibitor savolitinib and the PD-L1 inhibitor durvalumab did not reach the confirmed response rate endpoint in patients with metastatic papillary renal cancer but showed...
Black Women at High Risk of Breast Cancer May Face Obstacles in Receiving Preventive Care
Black women at high risk of developing breast cancer may face a variety of obstacles keeping them from receiving preventive care that could increase their chances of survival if they did develop the disease, according to a new study published by Padamsee et al in PLOS One. The new findings provide...
Racial/Ethnic Disparities in All-Cause and Cardiovascular Mortality Among Patients With Cancer
In an analysis reported in JACC: CardioOncology, Zhu et al found that in the United States, Black patients with cancer were at increased risk of all-cause mortality and cardiovascular (CVD) mortality compared with White patients, and that White patients were at increased risk of both outcomes...
How Patient Navigation Programs Are Helping Drive Equitable Care for Patients With Cancer and Improve Outcomes
Although patient navigation is increasingly recognized as an important component in the delivery of patient-centered cancer care, the service is not universally available across all cancer programs in the United States, often because of the concerns of extra cost without tangible financial...
American Cancer Society Data Show Colorectal Cancer Rates Are Rising in Younger Adults and Shifting to More Advanced Disease in People of All Ages
According to the American Cancer Society, colorectal cancer is the third most commonly diagnosed cancer and the third most common cause of cancer-related death in both men and women in the United States. However, it ranks second in cancer-related deaths overall, and is the leading cause of death in ...
Addition of Pembrolizumab to Pemetrexed/Platinum in the First-Line Treatment of Metastatic Nonsquamous NSCLC: 5-Year Outcomes in the KEYNOTE-189 Study
As reported in the Journal of Clinical Oncology by Marina C. Garassino, MD, and colleagues, 5-year follow-up in the phase III KEYNOTE-189 trial has shown maintained progression-free and overall survival benefits with the addition of pembrolizumab to pemetrexed and platinum chemotherapy in the...
Prediction Models for Kidney Failure in Long-Term Survivors of Childhood Cancer
In a study reported in the Journal of Clinical Oncology, Wu et al developed models for predicting kidney failure among 5-year survivors of childhood cancer. Study Details In the study, predictive models were developed using data from 25,483 survivors from the Childhood Cancer Survivor Study (CCSS)...
Hospital Surgical Volume May Impact Survival in Patients With Pancreatic Cancer Whose Minimally Invasive Surgery Is Converted to an Open Procedure
Patients with pancreatic ductal adenocarcinoma whose pancreatoduodenectomy is converted to an open (CTO) procedure from a minimally invasive procedure as a result of complications may fare better at institutions that perform more minimally invasive pancreatic cancer surgeries annually, according to ...
De-escalated Neoadjuvant T-DM1 With or Without ET vs Trastuzumab With ET in Hormone Receptor–Positive/HER2-Positive Early Breast Cancer
As reported in the Journal of Clinical Oncology by Nadia Harbeck, MD, PhD, and colleagues, 5-year follow-up from the phase II WSG-ADAPT-TP trial indicated that pathologic complete response (pCR) was associated with better outcomes irrespective of receipt of adjuvant chemotherapy among patients with ...
Combination Abatacept, Ruxolitinib, and/or Mechanical Ventilation May Decrease Mortality in Patients With Immune Checkpoint Inhibitor–Associated Cardiotoxicity
Although immune checkpoint inhibitors have substantially improved clinical outcomes in many cancer types, they have also been found to induce immune-related adverse events, including myocarditis, in about 1% of patients receiving the agents, which can lead to a mortality rate of up to 50%. Current...
Prevalence of High-Grade Serous Carcinoma at Risk-Reducing Salpingo-Oophorectomy in Asymptomatic Patients With BRCA1/2 Pathogenic Variants
In a Dutch study reported in the Journal of Clinical Oncology, Stroot et al identified the prevalence of high-grade serous carcinoma at risk-reducing salpingo-oophorectomy in asymptomatic BRCA1/2 pathogenic variant carriers. Study Details The study included asymptomatic BRCA1/2 pathogenic variant...
New Study Demonstrates Inferior Vena Cava Filters May Be Safe and Effective Way to Prevent Venous Thromboembolism
Researchers have discovered that few adverse events may be associated with the use of inferior vena cava filters to help prevent deep vein thrombosis from developing into pulmonary embolisms, according to a new study jointly published by Johnson et al in the Journal of Vascular and Interventional...
Urologic Oncologist Hyung Kim, MD, Named Chair of Cedars-Sinai Department of Urology
Cedars-Sinai has appointed urologic oncologist, surgeon, and research investigator Hyung Kim, MD, as the inaugural Chair of the newly established Department of Urology. “Dr. Kim is an outstanding clinical and academic leader who will strategically steer our urology enterprise,” said Shlomo Melmed, ...
ASCO Updates ‘Living’ Guidelines on Stage IV NSCLC Based on DESTINY-Lung01, CodeBreaK100, Other Trials
ASCO has updated its living guidelines for therapy for stage IV non–small cell lung cancer (NSCLC) with and without driver alterations based on newly available evidence in the field.1,2 “Living guidelines are becoming more important as the field of oncology expands and developments occur more...
ASCO Endorses CAP Guideline to Better Define Who Benefits From Immune Checkpoint Inhibitor Therapy
ASCO has endorsed a new guideline from the College of American Pathologists (CAP) on the use of mismatch repair (MMR) and microsatellite instability (MSI) testing, which could help oncologists more accurately identify patients who may be suitable candidates for immune checkpoint inhibitor ...
Expert Point of View: Breelyn A. Wilky, MD
Discussant of the INTRIGUE abstract, Breelyn A. Wilky, MD, Director of Sarcoma Medical Oncology, Deputy Associate Director for Clinical Research, University of Colorado, Aurora, called the data presented “compelling evidence of the power of ctDNA [circulating tumor DNA] to identify predictive...
INTRIGUE Study: Circulating Tumor DNA Analysis May Predict Optimal Treatment of Patients With GIST
Circulating tumor DNA (ctDNA) analysis of KIT exon mutations may help to predict which second-line therapy is best for patients with advanced gastrointestinal stromal tumor (GIST), according to data presented during the ASCO Plenary Series: January 2023 Session.1 Exploratory analysis of the phase...
Expert Point of View: Pretesh R. Patel, MD
Session co-moderator, Pretesh R. Patel, MD, Associate Professor of Radiation Oncology at Winship Cancer Institute of Emory University, shared his thoughts on the Neo-AEGIS1 findings with The ASCO Post. “I think we continue to have equipoise about chemoradiation and perioperative chemotherapy in...
Neo-AEGIS Trial Finds Two Approaches Comparable in Treating Advanced Esophageal Cancer
A randomized trial that sought to determine the optimal approach to treating locally advanced esophageal or gastroesophageal junction cancer has ended in “equipoise,” according to the investigators of the Neo-AEGIS trial. In a study reported at the 2023 ASCO GI Cancers Symposium, perioperative...
Expert Point of View: Laura Goff, MD, MSCI
Invited discussant Laura Goff, MD, MSCI, Associate Professor of Medicine and Executive Medical Director for the Cancer Patient Care Center at Vanderbilt-Ingram Cancer Center, Nashville, said that with the results of NAPOLI-3, clinicians have a third effective first-line regimen for metastatic...
First-Line NALIRIFOX Improves Survival in Metastatic Pancreatic Cancer
In the phase III NAPOLI-3 trial in previously untreated patients with metastatic pancreatic cancer, the NALIRIFOX regimen significantly improved overall survival and progression-free survival over nab-paclitaxel plus gemcitabine.1 NALIRIFOX, which contains liposomal irinotecan, fluorouracil,...
Have We Reached the Limits of Chemotherapy for Burkitt Lymphoma?
Burkitt lymphoma (BL) is a fascinating disease from which many groundbreaking medical and oncologic lessons have been learned. Since the Irish surgeon Denis P. Burkitt, MD, FRCS, FRS, first described rapidly enlarging jaw and facial tumors in Ugandan children in 1958,1 the study of BL has led to...
Recommendations for Promoting Sexual and Gender Minority Inclusion in Oncology Care
Approximately 10% of adults in the United States self-report being members of sexual and gender minorities (SGMs), which means that most oncologists will treat SGM patients in their practice. Here are some suggestions on how clinicians and oncology institutions can help SGM patients feel safe and...
Understanding the Health Disparities That Sexual and Gender Minorities Face in Oncology Care
In its programming for the 2022 ASCO Annual Meeting, ASCO included a special Education Session on “Gender-Based and Sexual Orientation Inequities: Promoting Inclusion, Visibility, and Data Accuracy in Oncology.” The session offered a comprehensive discussion on the challenges that sexual and gender ...
Expert Point of View: Dustin Deming, MD
The invited discussant of the SUNLIGHT trial, Dustin Deming, MD, the ACI/Schwenn Family Association Professor in the Division of Hematology, Medical Oncology, and Palliative Care and Director of JD Fluno Colorectal Cancer Precision Medicine at the University of Wisconsin, Madison, said the findings ...
Addition of Bevacizumab to Trifluridine/Tipiracil: New Standard of Care in Refractory Colorectal Cancer
In the open-label phase III SUNLIGHT trial, the addition of bevacizumab to trifluridine/tipiracil, also known as TAS-102, significantly improved overall survival in patients with metastatic treatment-refractory colorectal cancer,1 according to Josep Tabernero, MD, Head of the Department of Medical...
Whole-Genome Sequencing May Illuminate the Genetic Evolution of Classical Hodgkin Lymphoma
Researchers have discovered that whole-genome sequencing—rather than the current standard of exome sequencing—may allow physicians to better identify genetic changes that drive cancer development and growth, and create the most effective, personalized treatment plans for patients with classical...
Discordance of p16 and HPV DNA/RNA Status: Prognostic Implication in Squamous Cell Oropharyngeal Carcinoma
In a study reported in The Lancet Oncology, Hisham Mehanna, FRCS, and colleagues found that concordance and discordance of p16 immunohistochemistry and human papillomavirus (HPV) DNA/RNA testing were associated with different outcomes among patients with squamous cell oropharyngeal carcinoma....
Addition of Bortezomib to First-Line Dexamethasone, Rituximab, and Cyclophosphamide for Waldenström’s Macroglobulinemia
As reported in the Journal of Clinical Oncology by Buske et al, the European Consortium for Waldenström’s Macroglobulinemia (ECWM)-1 study has shown a numeric benefit in progression-free survival with the addition of bortezomib to dexamethasone, rituximab, and cyclophosphamide (DRC; B-DRC) in the...
Low Income Linked to High Recurrence Risk, Poorer Survival in Patients With ER-Positive Breast Cancer
Patients with early-stage estrogen receptor (ER)-positive breast cancer who live in low-income neighborhoods may be more likely to have more aggressive tumor biology and significantly lower overall survival than those living in higher-income neighborhoods, according to a new study published by Ma...
First-Line Tyrosine Kinase Inhibitor Therapy for Advanced Clear Cell Renal Cell Carcinoma: Temporary Treatment Cessation vs Continuation
As reported in The Lancet Oncology by Brown et al, the phase II/III STAR trial showed that noninferiority in overall survival and quality-adjusted life-years (QALYs) could not be concluded for temporary treatment cessation vs continuous treatment with first-line tyrosine kinase inhibitor therapy in ...
Triplet and Quadruplet Regimens in Smoldering Multiple Myeloma
Combination regimens beyond lenalidomide/dexamethasone were shown to significantly delay—and potentially prevent altogether—progression from smoldering disease to active multiple myeloma, according to researchers who reported findings from two studies at the 2022 American Society of Hematology...
Pediatric Patients With ALL Living Along the Texas-Mexico Border May Experience Lower Rates of Survival
Investigators have found that pediatric patients with acute lymphoblastic leukemia (ALL) who lived along the Texas-Mexico border were more likely to die within 5 years than those living in other areas of the state, according to a new study published by Castellanos et al in Cancer. Background...
KEYNOTE-859 Interim Analysis: Overall Survival Benefit for First-Line Pembrolizumab in Advanced Gastric Cancer
Results of the interim analysis of KEYNOTE-859 are in, and they confirm the overall survival benefit of first-line immunotherapy plus chemotherapy in advanced gastric cancer. Pembrolizumab plus a fluoropyrimidine- and platinum-containing doublet provided a statistically significant improvement in...
Abstracts of Interest on Novel Therapies for Gastrointestinal Cancers
As in the years before the COVID-19 pandemic, the 2023 ASCO GI Cancers Symposium—its 20th such gathering—played to a full ballroom. It featured a stellar lineup of experts in the field as well as high-quality, impactful research in esophageal, gastric, hepatocellular, pancreatic, biliary tract, and ...
President Biden Announces Key Appointments to National Cancer Advisory Board
On February 2, 2023, President Joseph Biden announced his intent to appoint six members to the National Cancer Advisory Board (NCAB). The NCAB plays an important role in guiding the Director of the National Cancer Institute in setting the course for the national cancer research program. The NCAB...
Intensified Drug Regimen Added to Standard of Care Improves Outcomes in Subset of Patients With High-Risk Prostate Cancer
In the phase III FORMULA-509 trial, the addition of abiraterone acetate/prednisone and apalutamide—compared with bicalutamide—to salvage radiation therapy plus 6 months of treatment with a gonadotropin-releasing hormone (GnRH) agonist failed to improve progression-free survival postprostatectomy in ...
Allogeneic HCT vs Consolidation Chemotherapy in Patients Aged 60 Years or Younger With Intermediate-Risk AML
In a German phase III trial reported in JAMA Oncology, Bornhäuser et al found that allogeneic hematopoietic cell transplantation (HCT) was not associated with improved overall survival vs standard consolidation chemotherapy in patients aged ≤ 60 years with cytogenetically defined intermediate-risk...
Encorafenib, Binimetinib, and Cetuximab in Previously Untreated Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer
In the phase II ANCHOR CRC trial reported in the Journal of Clinical Oncology, Eric Van Cutsem, MD, PhD, and colleagues found that the combination of encorafenib, binimetinib, and cetuximab produced an objective response in nearly half of previously untreated patients with BRAF V600E–mutant...
Cancer Symptom Algorithm May Aid Oncologists in Predicting Which Patients Are at Risk for Unplanned ED Visits
Researchers have found that an algorithm that calculates patient-reported symptom complexity scores may help oncologists identify patients who are at an increased risk for unplanned visits to the emergency department (ED), creating the potential for additional proactive care and reduced health-care ...
TALAPRO-2: Talazoparib Plus Enzalutamide Improves Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer
The TALAPRO-2 phase III clinical trial found that combining the poly (ADP-ribose) polymerase (PARP) inhibitor talazoparib with the androgen receptor inhibitor enzalutamide resulted in significantly better progression-free survival vs the current standard of care for patients with metastatic...
Expert Point of View: Ajay K. Nooka, MD, MPH
Insights on findings from the phase II MonumenTAL-1 trial1 were offered by Ajay K. Nooka, MD, MPH, Professor in the Department of Hematology and Medical Oncology, and Medical Director of the Winship Data and Technology Applications Shared Resource, Winship Cancer Institute, Emory University School ...
Study Shows Activity of Talquetamab in Highly Refractory Multiple Myeloma
In the phase I/II MonumenTAL-1 trial, the novel bispecific antibody talquetamab produced responses in more than 70% of heavily pretreated patients with multiple myeloma.1 Of note, the safety profile confirmed results of the phase I portion of the study (recently published in TheNew England Journal...
Expert Point of View: Urvi A. Shah, MD
Urvi A. Shah, MD, Assistant Attending at Memorial Sloan Kettering Cancer Center and Assistant Professor at Weill Cornell Medicine, New York, moderated the session where the MagnetisMM trial updates1,2 were reported and was interviewed by The ASCO Post. Elranatamab vs Teclistamab Dr. Shah noted...
Complete Response to Glofitamab at End of Treatment Heralds Prolonged Remission in Lymphoma
Patients with large B-cell lymphoma who achieve a complete response to glofitamab are very likely to remain in remission 12 months after the end of treatment, according to Martin Hutchings, MD, PhD, of Rigshospitalet in Copenhagen, who reported these findings at the 2022 American Society of...
Study Suggests Ibrutinib May Obviate Need for Autologous Stem Cell Transplantation in Some Younger Patients With Mantle Cell Lymphoma
Although longer follow-up is needed, the results of the three-arm randomized TRIANGLE study suggest that the tyrosine kinase inhibitor ibrutinib may replace autologous stem cell transplantation (ASCT) after chemoimmunotherapy in younger patients with previously untreated mantle cell lymphoma (MCL). ...
CLL2-GIVe Trial: Regimen of Obinutuzumab, Ibrutinib, and Venetoclax Effective in High-Risk CLL
The first-line combination of obinutuzumab, ibrutinib, and venetoclax appears to be effective in treating high-risk chronic lymphocytic leukemia (CLL), according to data presented at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition.1 Results of the CLL2-GIVe trial, which...
Ponatinib and Blinatumomab Combination Safe and Effective in Patients With Newly Diagnosed, Ph-Positive ALL
The combination of ponatinib and blinatumomab has led to rapid and durable remissions in patients with newly diagnosed Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL), according to data presented at the 2022 American Society of Hematology (ASH) Annual Meeting and...
